| name | Dapsone |
| Classification | Antibacterial, Antimalarial, Antiprotozoal |
| Pharmacokinetics | Dapsone is primarily metabolized in the liver. The elimination half-life is approximately 24 hours. It can accumulate in the body with repeated doses. Absorption is relatively rapid and complete after oral administration. The drug is highly protein-bound. Significant accumulation can occur with prolonged treatment, particularly in individuals with impaired hepatic function. |
| suggested dosage | | male patient 25 70kg | The recommended dosage for various conditions is highly variable. It's crucial to follow the specific instructions provided by a healthcare professional. Generic dosing guidelines for common conditions like leprosy and dermatitis herpetiformis can be found in professional medical texts. | | typical initial dose | 50mg/day and adjusted as needed based on the clinical response and patient tolerance. |
|
| indications | | 1 | Leprosy (Hansen's disease) | | 2 | Pneumocystis jirovecii pneumonia (PJP) | | 3 | Dermatitis herpetiformis | | 4 | Severe acne | | 5 | Severe malaria |
|
| Safety in pregnancy | Dapsone use during pregnancy requires careful consideration and consultation with a healthcare professional. Potential risks to the developing fetus are possible. The benefits and risks should be weighed against each other in individual cases. |
| Safety in breastfeeding | Dapsone can pass into breast milk. It's advisable to carefully weigh the potential benefits against the potential risks for the infant. Consultation with a healthcare professional is necessary. |
| side effects | | 1 | Hemolytic anemia (rare, but potentially serious) | | 2 | Gastrointestinal upset (nausea, vomiting, diarrhea) | | 3 | Headache | | 4 | Peripheral neuropathy | | 5 | Skin rash | | 6 | Methylene blue toxicity | | 7 | Pancytopenia | | 8 | Hepatotoxicity | | 9 | Photosensitivity |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity or allergy to dapsone or related sulfones | | 2 | Severe blood disorders (e.g., aplastic anemia) | | 3 | Severe liver disease | | 4 | Glucose-6-phosphate dehydrogenase deficiency (G6PD) |
|
| interactions | | 1 | Concurrent use with certain medications, including other drugs that affect liver metabolism, can increase the risk of side effects or potentially reduce their effectiveness | | 2 | Caution with concurrent use of other medications affecting the liver or blood, such as mefloquine and methotrexate. | | 3 | Inhibitors of CYP450 enzymes, and medications known to cause blood dyscrasias |
|
| warnings and precautions | | 1 | Regular monitoring of blood counts, especially hemoglobin and reticulocytes, is essential during dapsone treatment, particularly in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD). | | 2 | Patients with a history of liver or kidney disease require careful monitoring. | | 3 | Patients should be informed about the possibility of a skin reaction to the drug. | | 4 | Patients should inform their healthcare provider if they experience symptoms like fatigue, weakness, or rapid heartbeat. |
|
| additional informations | | 1 | Dapsone can cause a false-positive result in urine glucose tests. | | 2 | Careful observation is needed for signs of peripheral neuropathy, especially in those with diabetes or renal impairment | | 3 | Use with caution in patients with cardiac problems | | 4 | Dosage should be adjusted based on individual patient response and potential side effects |
|
| important notes | This information is for educational purposes only and should not be considered a substitute for professional medical advice. Always consult with a qualified healthcare provider before starting any new medication or changing your current treatment plan. Dosage and use vary depending on the specific medical condition. |
